Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance [10][21]. Core Insights - In 2023, the company achieved a revenue of 1.017 billion yuan, representing a year-over-year increase of 67.51%. The net profit attributable to shareholders was 272 million yuan, up 40.07% year-over-year [1][10]. - The company reported a strong order intake of 1.36 billion yuan, a 35.06% increase year-over-year, with a backlog of 1.586 billion yuan, reflecting an 18.90% growth [1][5]. - The first quarter of 2024 continued the growth trend, with revenues of 216 million yuan, a 34.04% increase year-over-year, and a net profit of 50 million yuan, up 42.06% [1][10]. Financial Performance Summary - Revenue by segment in 2023: - Preclinical pharmaceutical research: 338 million yuan (yoy +54.81%) - R&D technology transformation: 392 million yuan (yoy +77.66%) - Clinical services: 193 million yuan (yoy +141.25%) - CDMO: 52 million yuan (yoy +152.35%) - Equity sharing: 30 million yuan (yoy -48.74%) [5]. - The company is focusing on enhancing its competitive advantage in entrusted R&D services while actively promoting the transformation of R&D results [5]. Earnings Forecast - The company is projected to achieve net profits of 368 million yuan, 491 million yuan, and 635 million yuan for the years 2024, 2025, and 2026, respectively, with corresponding PE ratios of 20.0, 15.0, and 11.6 [10][11].
业绩及订单高速增长，自研项目迈入收获期